These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23127435)

  • 1. Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis.
    Kwong LM
    Orthopedics; 2012 Nov; 35(11):919; discussion 919. PubMed ID: 23127435
    [No Abstract]   [Full Text] [Related]  

  • 2. Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis.
    Kwong LM
    Orthopedics; 2012 Jun; 35(6):e932-8;discussion e939. PubMed ID: 22691670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban for thromboprophylaxis in patients undergoing major orthopedic surgery.
    Melillo SN; Scanlon JV; Exter BP; Steinberg M; Jarvis CI
    Ann Pharmacother; 2010 Jun; 44(6):1061-71. PubMed ID: 20424181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective factor Xa inhibition for thromboprophylaxis.
    Eikelboom JW; Weitz JI
    Lancet; 2008 Jul; 372(9632):6-8. PubMed ID: 18582929
    [No Abstract]   [Full Text] [Related]  

  • 5. Rivaroxaban for thromboembolism prophylaxis after orthopaedic surgery.
    Phillips SN; Rogers BA; Foote J
    Anaesthesia; 2010 Oct; 65(10):1043-4. PubMed ID: 21198472
    [No Abstract]   [Full Text] [Related]  

  • 6. Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty.
    Borris LC
    Arch Orthop Trauma Surg; 2010 May; 130(5):583-9. PubMed ID: 19565250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New oral anticoagulants: not quite there yet.
    Karthikeyan G; Eikelboom JW; Hirsh J
    Pol Arch Med Wewn; 2009; 119(1-2):53-8. PubMed ID: 19341179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban, a new, oral, direct factor Xa inhibitor for thromboprophylaxis after major joint arthroplasty.
    Borris LC
    Expert Opin Pharmacother; 2009 Apr; 10(6):1083-8. PubMed ID: 19351271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upcoming oral factor Xa inhibitors for venous thromboembolism prophylaxis in patients undergoing major orthopedic surgery: rivaroxaban (Xarelto) and apixaban (Eliquis) review.
    Lee S; White CM
    Conn Med; 2012 Jan; 76(1):39-42. PubMed ID: 22372178
    [No Abstract]   [Full Text] [Related]  

  • 10. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF; Ganetsky V; Spinler SA
    Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    Vink R; Sohne M
    N Engl J Med; 2013 May; 368(20):1945. PubMed ID: 23675668
    [No Abstract]   [Full Text] [Related]  

  • 12. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    Derksen RJ; Mulder WM; Mulder JW
    N Engl J Med; 2013 May; 368(20):1945. PubMed ID: 23675667
    [No Abstract]   [Full Text] [Related]  

  • 13. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    Alameddine R; Husari A
    N Engl J Med; 2013 May; 368(20):1944-5. PubMed ID: 23675666
    [No Abstract]   [Full Text] [Related]  

  • 14. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    Cohen AT; Spiro TE; Spyropoulos AC;
    N Engl J Med; 2013 May; 368(20):1945-6. PubMed ID: 23675665
    [No Abstract]   [Full Text] [Related]  

  • 15. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
    Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
    Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
    Loke YK; Kwok CS
    J Clin Pharm Ther; 2011 Feb; 36(1):111-24. PubMed ID: 21198726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time.
    Mani H; Hesse C; Stratmann G; Lindhoff-Last E
    Thromb Haemost; 2011 Jul; 106(1):156-64. PubMed ID: 21655672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CONKO-011: Evaluation of patient satisfaction with the treatment of acute venous thromboembolism with rivaroxaban or low molecular weight heparin in cancer patients. A randomized phase III study].
    Riess H; Sinn M; Kreher S;
    Dtsch Med Wochenschr; 2015 Jun; 140 Suppl 1():S22-3. PubMed ID: 26069043
    [No Abstract]   [Full Text] [Related]  

  • 19. Patient-reported compliance with thromboprophylaxis using an oral factor Xa inhibitor (rivaroxaban) following total hip and total knee arthroplasty.
    Carrothers AD; Rodriguez-Elizalde SR; Rogers BA; Razmjou H; Gollish JD; Murnaghan JJ
    J Arthroplasty; 2014 Jul; 29(7):1463-7. PubMed ID: 24768192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
    Monreal M; Folkerts K; Diamantopoulos A; Imberti D; Brosa M
    Thromb Haemost; 2013 Nov; 110(5):987-94. PubMed ID: 23965805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.